GB202015916D0 - Combination therapy - Google Patents
Combination therapyInfo
- Publication number
- GB202015916D0 GB202015916D0 GBGB2015916.6A GB202015916A GB202015916D0 GB 202015916 D0 GB202015916 D0 GB 202015916D0 GB 202015916 A GB202015916 A GB 202015916A GB 202015916 D0 GB202015916 D0 GB 202015916D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- combination therapy
- therapy
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2015916.6A GB202015916D0 (en) | 2020-10-07 | 2020-10-07 | Combination therapy |
| PCT/EP2021/077504 WO2022074033A1 (en) | 2020-10-07 | 2021-10-06 | Combination therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2015916.6A GB202015916D0 (en) | 2020-10-07 | 2020-10-07 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202015916D0 true GB202015916D0 (en) | 2020-11-18 |
Family
ID=73139056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2015916.6A Ceased GB202015916D0 (en) | 2020-10-07 | 2020-10-07 | Combination therapy |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202015916D0 (en) |
| WO (1) | WO2022074033A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004045512A2 (en) | 2002-11-15 | 2004-06-03 | Genmab A/S | Human monoclonal antibodies against cd25 |
| WO2007044515A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| WO2014057119A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2016083468A1 (en) | 2014-11-25 | 2016-06-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| WO2016166341A1 (en) | 2015-04-15 | 2016-10-20 | Van Berkel Patricius Hendrikus Cornelis | Site-specific antibody-drug conjugates |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB201811364D0 (en) * | 2018-07-11 | 2018-08-29 | Adc Therapeutics Sa | Combination therapy |
-
2020
- 2020-10-07 GB GBGB2015916.6A patent/GB202015916D0/en not_active Ceased
-
2021
- 2021-10-06 WO PCT/EP2021/077504 patent/WO2022074033A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004045512A2 (en) | 2002-11-15 | 2004-06-03 | Genmab A/S | Human monoclonal antibodies against cd25 |
| WO2007044515A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| WO2014057119A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2016083468A1 (en) | 2014-11-25 | 2016-06-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| WO2016166341A1 (en) | 2015-04-15 | 2016-10-20 | Van Berkel Patricius Hendrikus Cornelis | Site-specific antibody-drug conjugates |
Non-Patent Citations (45)
| Title |
|---|
| "Genbank", Database accession no. NM_000417 |
| "Guideline on clinical trials in small populations", 1 February 2007, FDA AND EMEA |
| "Uniprot/Swiss-Prot", Database accession no. P60568-1 |
| ANGEW CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186 |
| ARCE VARGAS ET AL., IMMUNITY, vol. 46, 18 April 2017 (2017-04-18), pages 1 - 10 |
| ARCE VARGAS ET AL., IMMUNITY, vol. 46, 2017, pages 1 - 10 |
| ARENAS-RAMIREZ N ET AL., TRENDS IN IMMUNOLOGY, vol. 36, no. 12, 2015, pages 763 - 7777 |
| CARTER, P., NATURE REVIEWS IMMUNOLOGY, vol. 6, 2006, pages 343 - 357 |
| CAS , no. 1957239-90-5 |
| CAS, no. 391210-10-9 |
| CATANIA ET AL., CELL MIGR. ADHES., vol. 9, 2015, pages 1 - 2,14-21 |
| CHESON, SOUTH ASIAN J CANCER, vol. 3, no. 1, January 2014 (2014-01-01), pages 66 - 70 |
| CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 |
| FIELDING A., HAEMATOLOGICA, vol. 95, no. 1, January 2010 (2010-01-01), pages 8 - 12 |
| FLYNN ET AL., MOL CANCER THER, 2016 |
| FRIEDMANN MC, PNAS, vol. 93, no. 5, 1996, pages 2077 - 82 |
| GILLESSESN ET AL., EUR J CANCER, vol. 49, no. 1, January 2013 (2013-01-01), pages 35 - 44 |
| GILLIES ET AL., BLOOD, vol. 105, no. 10, 15 May 2005 (2005-05-15), pages 3972 - 8 |
| HAMANN P., EXPERT OPIN. THER. PATENTS, vol. 15, no. 9, 2005, pages 1087 - 1103 |
| JANEWAY, C.TRAVERS, P.WALPORT, M.SHLOMCHIK: "Immuno Biology", 2001, GARLAND PUBLISHING |
| JOURNAL OF CLINICAL ONCOLOGY, vol. 37, pages e14220 - e14220 |
| KLEIN ET AL., ONCOIMMUNOLOGY, vol. 6, no. 3, 11 January 2017 (2017-01-11), pages e1277306 |
| KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 |
| KOVTUN ET AL., CANCER RES., vol. 66, no. 4, 2006, pages 2328 - 2337 |
| KS PEGGS ET AL., CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 157, 2009, pages 9 - 19 |
| LAMBERT J., CURRENT OPIN. IN PHARMACOL., vol. 5, 2005, pages 543 - 549 |
| LIAO W. ET AL., CURRENT OPINION IN IMMUNOLOGY, vol. 23, no. 5, 2011, pages 598 - 604 |
| LIAO W. ET AL., IMMUNITY, vol. 38, no. 1, 2013, pages 13 - 25 |
| LONBERG, CURR. OPINION, vol. 20, no. 4, 2008, pages 450 - 459 |
| LOPES, JE. ET AL., J IMMUNOTHER CANCER, vol. 8, no. 1, April 2020 (2020-04-01), pages e000673 |
| MALEK TR ET AL., IMMUNITY, vol. 33, no. 2, 2010, pages 153 - 65 |
| MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597 |
| MILLER ET AL., JOUR. OF IMMUNOLOGY, vol. 170, 2003, pages 4854 - 4861 |
| MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855 |
| PAYNE, G., CANCER CELL, vol. 3, 2003, pages 207 - 212 |
| SCHLIEMANN ET AL., CANCER IMMUNOL. RES., vol. 3, 2015, pages 547 - 556 |
| SILVA DA. ET AL., NATURE, vol. 565, no. 7738, 2019, pages 186 - 191 |
| SYRIGOSEPENETOS, ANTICANCER RESEARCH, vol. 19, 1999, pages 605 - 614 |
| TANAKA, A. ET AL., CELL RES, vol. 27, no. 1, January 2017 (2017-01-01), pages 109 - 118 |
| TANAKA, A. ET AL., CELL RES., vol. 27, no. 1, January 2017 (2017-01-01), pages 109 - 118 |
| TRAIL ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337 |
| TREGMENETRIER-CAUX, C. ET AL., TARG ONCOL, vol. 7, 2012, pages 15 - 28 |
| WANG X. ET AL., SCIENCE, vol. 310, no. 5751, 2005, pages 1159 - 63 |
| WU ET AL., NATURE BIOTECH, vol. 23, no. 9, 2005, pages 1137 - 1145 |
| XIE ET AL., EXPERT. OPIN. BIOL. THER., vol. 6, no. 3, 2006, pages 281 - 291 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022074033A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202111288D0 (en) | Combination therapy | |
| GB202108303D0 (en) | Therapy | |
| GB202004189D0 (en) | Combination therapy | |
| IL304223A (en) | Combination therapy | |
| GB202109377D0 (en) | Combination therapy | |
| GB202109375D0 (en) | Combination therapy | |
| GB202109373D0 (en) | Combination therapy | |
| GB202107824D0 (en) | Combination therapy | |
| GB202107706D0 (en) | Combination therapy | |
| GB202107709D0 (en) | Combination therapy | |
| GB202107713D0 (en) | Combination therapy | |
| GB202104037D0 (en) | Combination therapy | |
| GB202015916D0 (en) | Combination therapy | |
| GB202012161D0 (en) | Combination therapy | |
| GB202009178D0 (en) | Combination therapy | |
| GB202117706D0 (en) | Therapy | |
| GB202111035D0 (en) | Therapy | |
| GB202109893D0 (en) | PeptiBAC therapy | |
| GB202104427D0 (en) | Therapy | |
| GB202103164D0 (en) | Therapy | |
| GB202102211D0 (en) | PeptiBAC therapy | |
| GB202019218D0 (en) | Therapy | |
| GB202017598D0 (en) | Therapy | |
| GB202017554D0 (en) | Therapy | |
| GB202015778D0 (en) | Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |